Vertex Pharmaceuticals Non-GAAP EPS of $3.76 beats by $0.25, revenue of $2.3B in-line
Vertex Pharmaceuticals press release  (NASDAQ:VRTX): Q4  Non-GAAP EPS of $3.76  beats by $0.25.
Revenue of $2.3B (+11.1% Y/Y) in-line.
The company provides full year 2023 product revenue guidance of $9.55 billionÂ to $9.7 billion.
Exa-cel regulatory submissions validated in the EU andÂ U.K.;Â U.S.Â rolling BLA submission underway.
Advancing broad and diverse clinical pipeline, with multiple clinical milestones expected in 2023.
Cash, cash equivalents and marketable securities as of December 31, 2022 were $10.8 billion, compared to $7.5 billion as of December 31, 2021. The increase was primarily driven by strong revenue growth and operating cash flow, partially offset by income tax payments and our acquisition of ViaCyte.